The market is growing due to the rising number of advanced product launched, increasing availability and affordability of tests, and surging prevalence of genetic diseases across the globe. When type is taken into consideration, the market is divided into targeted carrier screening and expanded carrier screening.

Between these two, the expanded carrier screening division held the larger share of the market in 2019, owing to the extensive usage of NGS and other technologies across the globe. In addition to this, the expanded approach allows for the testing of a number of diseases at once. The category is further predicted to register the faster growth during the forecast period. In terms of application, the market is categorized into fragile X syndrome, cystic fibrosis, sickle cell disease, spinal muscular atrophy, and thalassemia.

When technology is considered, the graphene market is divided into microarray, DNA sequencing, and polyamerase chain reaction. Out of these, the DNA sequencing division is projected to witness the highest CAGR during the forecast period, as the cost of the technology is low. In addition to this, high expertise in the field of bioinformatics is not required for using this technology. In recent years, DAN sequencing is being integrated with a large number of user-friendly tools, thereby making the screening process quite simple.

The prevalence of genetic diseases has been rising rapidly, which is resulting in the growth of the carrier screening market. The severity and risk of genetic disease largely depend on ancestors and parent’s carrier status, owing to which, it is important to screen these diseases early. The American College of Obstetricians and Gynecologists recommend pregnant women to get tested for detecting the risk of such diseases early. Because genetic disease account for a high infant mortality rate, parent are becoming highly concerned regarding their children, which is predicted to drive the market.